Interpace OTC Stock Analysis


USD 1.85  0.05  2.63%   

The big decline in price over the last few months for Interpace Diagmay raise some interest from shareholders. The stock closed today at a share price of 1.85 on 1,065 in trading volume. The company directors and management failed to add value to investors and position the firm supply of money to exploit market volatility in August. However, diversifying your holdings with Interpace Diag Group or similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 6.44. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Interpace Diag Group partners.
Please see Risk vs Return Analysis.
The Interpace Diag otc stock analysis report makes it easy to digest most publicly released information about Interpace Diag and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Interpace OTC Stock analysis module also helps to analyze the Interpace Diag price relationship with some important fundamental indicators such as market cap and management efficiency.

Interpace OTC Stock Analysis Notes

About 27.0% of the company shares are held by company insiders. The company recorded a loss per share of 7.32. Interpace Diag Group had not issued any dividends in recent years. The entity had 1-10 split on the 15th of January 2020. Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey. Interpace Diag operates under Diagnostics Research classification in the United States and is traded on OTC Exchange. It employs 147 people.The quote for Interpace Diag Group is listed on Over The Counter exchange (i.e., OTC), and the entity is not required to meet listing requirements such as those found on the Nasdaq, NYSE, or AMEX exchanges. To learn more about Interpace Diag Group call Jack CPA at 855 776 6419 or check out

Interpace Diag Group Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more otcs at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Interpace Diag's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Interpace Diag Group or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Interpace Diag Group generated a negative expected return over the last 90 days
Interpace Diag Group has high historical volatility and very poor performance
Interpace Diag Group may become a speculative penny stock
Interpace Diag Group has a very high chance of going through financial distress in the upcoming years
The company currently holds 14.37 M in liabilities with Debt to Equity (D/E) ratio of 6.55, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Interpace Diag Group has a current ratio of 0.76, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Interpace Diag until it has trouble settling it off, either with new capital or with free cash flow. So, Interpace Diag's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Interpace Diag Group sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Interpace to invest in growth at high rates of return. When we think about Interpace Diag's use of debt, we should always consider it together with cash and equity.
The entity reported the previous year's revenue of 41.86 M. Net Loss for the year was (12.79 M) with profit before overhead, payroll, taxes, and interest of 17.95 M.
Interpace Diag Group currently holds about 2.85 M in cash with (4.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.67.
Roughly 27.0% of Interpace Diag shares are held by company insiders
Latest headline from BioVIT acquires Sekisuis XenoTech CRO for undisclosed price - FierceBiotech

Interpace Diag Group Upcoming and Recent Events

Earnings reports are used by Interpace Diag to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Interpace Diag previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report30th of March 2022
Next Financial Report10th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End30th of March 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Interpace Diag SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Interpace Diag prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Interpace Diag investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Interpace Diag Group specific information freely available to individual and institutional investors to make a timely investment decision.
7th of September 2022
Financial Statements and Exhibits. Regulation FD Disclosure. Completion of Acquisition or Disposition of Assets. Entry into a Material Definitive Agreement
15th of August 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
16th of May 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
10th of May 2022
Financial Statements and Exhibits. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. Entry into a Material Definitive Agreement
14th of April 2022
Financial Statements and Exhibits. Changes in Registrant's Certifying Accountant
31st of March 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
10th of February 2022
Unclassified Corporate Event
1st of February 2022
Unclassified Corporate Event

Interpace Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Interpace Diag is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Interpace Diag Group backward and forwards among themselves. Interpace Diag's institutional investor refers to the entity that pools money to purchase Interpace Diag's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Hrt Financial LpCommon Shares11.1 K52 K
Retirement Group LlcCommon Shares1000K
Tower Research Capital Llc TrcCommon Shares1771000
Blackrock IncCommon Shares117.2 K368 K
Vanguard Group IncCommon Shares80.6 K253 K
Geode Capital Management LlcCommon Shares32.5 K101 K
Squarepoint Ops LlcCommon Shares20.8 K65 K
Note, although Interpace Diag's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Interpace Market Capitalization

The company currently falls under 'Nano-Cap' category with current market capitalization of 7.93 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Interpace Diag's market, we take the total number of its shares issued and multiply it by Interpace Diag's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Interpace Profitablity

Interpace Diag's profitability indicators refer to fundamental financial ratios that showcase Interpace Diag's ability to generate income relative to its revenue or operating costs. If, let's say, Interpace Diag is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Interpace Diag's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Interpace Diag's profitability requires more research than a typical breakdown of Interpace Diag's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (31.02) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (26.57) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -0.27.

Management Efficiency

The entity has return on total asset (ROA) of (16.91) % which means that it has lost $16.91 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (161.49) %, meaning that it created substantial loss on money invested by shareholders. Interpace Diag management efficiency ratios could be used to measure how well interpace diag group manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 29th of September, Interpace Diag retains the risk adjusted performance of (0.12), and Market Risk Adjusted Performance of (0.85). Interpace Diag technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Simply put, you can use this information to find out if the firm will indeed mirror its model of historical price patterns, or the prices will eventually revert. We have analyzed and interpolated nineteen technical drivers for Interpace Diag Group, which can be compared to its competitors. Please check out Interpace Diag Group information ratio, potential upside, as well as the relationship between the Potential Upside and kurtosis to decide if Interpace Diag is priced fairly, providing market reflects its last-minute price of 1.85 per share. Please also validate Interpace Diag Group total risk alpha, which is currently at (0.40) to confirm the company can sustain itself at a future point.

Interpace Diag Group Price Movement Analysis

The output start index for this execution was twenty-nine with a total number of output elements of thirty-two. The Moving Average is predictive technique used to analyze Interpace Diag Group price data points by creating a series of averages of different subsets of Interpace Diag entire price series.

Interpace Diag Group Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Interpace Diag insiders, such as employees or executives, is commonly permitted as long as it does not rely on Interpace Diag's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Interpace Diag insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Interpace Diag Predictive Daily Indicators

Interpace Diag intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Interpace Diag otc stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Interpace Diag Forecast Models

Interpace Diag time-series forecasting models is one of many Interpace Diag's otc stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Interpace Diag's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Interpace OTC Stock Analysis

OTC Stock analysis is the technique used by a trader or investor to examine and evaluate how Interpace Diag prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Interpace shares will generate the highest return on investment. We also built our otc analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual OTC such as Interpace Diag. By using and applying Interpace OTC Stock analysis, traders can create a robust methodology for identifying Interpace entry and exit points for their positions.
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey. Interpace Diag operates under Diagnostics Research classification in the United States and is traded on OTC Exchange. It employs 147 people.

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our otc stock analysis tools, you can find out how much better you can do when adding Interpace Diag to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Price Transformation Now


Price Transformation

Use Price Transformation models to analyze depth of different equity instruments across global markets
All  Next Launch Module
Please see Risk vs Return Analysis. You can also try Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.

Complementary Tools for analysis

When running Interpace Diag Group price analysis, check to measure Interpace Diag's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Interpace Diag is operating at the current time. Most of Interpace Diag's value examination focuses on studying past and present price action to predict the probability of Interpace Diag's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Interpace Diag's price. Additionally, you may evaluate how the addition of Interpace Diag to your portfolios can decrease your overall portfolio volatility.
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Is Interpace Diag's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Interpace Diag. If investors know Interpace will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Interpace Diag listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Interpace Diag Group is measured differently than its book value, which is the value of Interpace that is recorded on the company's balance sheet. Investors also form their own opinion of Interpace Diag's value that differs from its market value or its book value, called intrinsic value, which is Interpace Diag's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Interpace Diag's market value can be influenced by many factors that don't directly affect Interpace Diag's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Interpace Diag's value and its price as these two are different measures arrived at by different means. Investors typically determine Interpace Diag value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Interpace Diag's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.